Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH). It carries a trans-3-hexenoyl modification attached to the N-terminal tyrosine residue. This chemical modification protects the peptide from rapid degradation by dipeptidyl peptidase IV (DPP-IV), greatly improving molecular stability compared with native GHRH and extending its biological half-life in laboratory research models.

In preclinical research, Tesamorelin selectively binds to GHRH receptors located on somatotroph cells within the anterior pituitary gland. The receptor activation triggers the pulsatile release of endogenous growth hormone, which subsequently stimulates the hepatic synthesis and secretion of IGF-1. Research investigations mainly focus on its regulatory effects on body composition, visceral adipose tissue metabolism, lipid profiles, and endocrine homeostasis. Studies also explore its influence on connective tissue, cellular inflammatory response, and metabolic signaling pathways associated with fat redistribution.

This research-grade peptide is produced via solid-phase peptide synthesis. Crude peptide material undergoes preparative HPLC purification, sterile filtration and vacuum lyophilization to form stable dry powder. Lyophilization effectively minimizes peptide hydrolysis and oxidation during long-term storage. Each batch is fully tested in the quality control laboratory, including HPLC purity detection, mass spectrometry identity confirmation, moisture content analysis, endotoxin testing and residual solvent inspection, to ensure reliable performance for in vitro cell assays and animal model studies. As a relatively large polypeptide, Tesamorelin is sensitive to high temperature, strong light and repeated freeze-thaw operations, which may lead to structural fragmentation and activity loss during laboratory handling.